US Pharma MarketingBiotech has a new startup model: Small team, big check and Chinese assets
The so-called NewCo model of value creation has been around for years, but its use with assets connected to China appears to be increasing, as the world’s second-most populous country experiences a renaissance in its drug development industry. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the…
A new flavor of company is shaking up how biotechs are built.
Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large checks and one ...
Source: Endpoints News